The global Glabridin Cas 59870 68 7 market closed 2024 with a valuation of $8.34 billion. Using a 5.4% compound annual growth rate, the market is expected to reach approximately $13.4 billion by 2033. Three forces explain the trajectory. First, restrictive rules on hydroquinone and mercury-based whiteners in the Philippines, Japan, and EU member states make botanical actives a dependable regulatory alternative. Second, clinical evidence supports glabridin's tyrosinase-inhibiting activity, and formulators now position it as an evidence-led component in high-ticket skin care. Third, supply-side investment in HPLC purification has improved consistency, lowering entry barriers for medium-sized personal care brands.

The demand base is not uniform. Cosmetics applications account for an estimated 64% of total revenue, while pharmaceutical applications contribute the remaining 36%. Formulators are using the Glabridin Powder Market to step away from low-stability liquid extracts and toward standardized powder blends. This improves batch-to-batch uniformity and simplifies cold-chain logistics. The same substitution dynamic is inflating the Cosmetic Grade Botanicals Market, where brands replace synthetic depigmenting agents with ingredients that meet clean-label and sustainability criteria.

Strategic planners should note three structural realities. Asia-Pacific is the largest regional revenue pool and the origin of most licensed extract manufacturing. Europe represents the most regulatory-intensive demand region, requiring rigorous documentation and higher purity grades. North America remains a steady consumer of high-purity glabridin for clinical testing and premium skin care, while pharmaceutical applications are still nascent but carry higher price tolerance. As product development shifts to formulas with a 90-98% assay, commodity-grade extract volumes will become less central to revenue growth.

Cosmetics is the largest application segment and will remain the dominant revenue pocket through 2033. Within this application, skin-tone-evening products drive most demand, but anti-aging and post-procedure care formulations are becoming relevant. The Skin Lightening Cosmetics Market is leaning on bioactive compounds that deliver visible results without compromising the skin barrier. Glabridin's anti-inflammatory properties position it for sensitive-skin products, which extends use beyond specialist whitening lines and into daily moisturizers, serums, and sun-care aftercare.

Demand is splitting by purity. HPLC 20 percent and HPLC 40 percent remain shelf-stable commodity inputs for lower-priced creams, while HPLC 90 percent and HPLC 98 percent glabridin are preferred by medical-grade and premium cosmeceutical suppliers. The HPLC Purified Glabridin Market has expanded faster than the overall application benchmark because formulators need documented limits for lead, arsenic, and residual solvents. Product launches in Korea and China increasingly state the purity percentage on ingredient disclosure sheets, allowing consumers to compare concentrations. Suppliers capable of releasing each batch with an HPLC certificate are earning preferred-seller status in Japan and Western Europe.

Powder is the dominant product format for cosmetic application, accounting for close to 55% of glabridin revenue in the base year. Liquid formats are used when a customer needs direct dispersion into water-phase formulas, but they lose stability more quickly. Capsules and other novel formats are small and mostly tied to oral nutricosmetics. As a stabilizer in emulsions, micronized glabridin powder improves solubility at low use rates: typical finishing concentrations are 0.1-0.5% in leave-on cosmetic products. Glabridin share of the broader Natural Skin Brighteners Market has stabilized at roughly one-fifth of botanical whitening actives, behind kojic acid and alpha-arbutin but ahead of licorice chalcones.

Cosmetic-grade suppliers face pressure on two fronts. High-purity product commands premium pricing and stronger margins, but the purification process creates yield losses; extraction from licorice roots typically yields only 0.5-2.5% glabridin before chromatographic polishing. Producers that integrate downstream formulation support, dermatological test documentation, and stability data are converting those costs into defensive differentiation. Application revenue from Asia-Pacific grows fastest, while European and North American buyers are more likely to purchase smaller volumes at higher purity and pay for regulatory dossier support. The share of cosmetics application is therefore expected to expand from 64% in 2024 to just above 67% by 2033.

Primary demand catalysts are regulatory substitution, clinical validation, and rising acceptance of oral dermal supplements. ASEAN health officials have phased out mercury-based whiteners and permitted only low hydroquinone concentrations; these restrictions create immediate conversion demand for glabridin-based creams. In parallel, the Pharmaceutical Plant Extracts Market shows renewed interest in glabridin as a topical anti-inflammatory agent. Pharmaceutical pilots require GMP-grade raw material, high-purity reference standards, and batch release documentation. Those trials do not yet generate large volumes, but they validate premium pricing and open hospital-dermatology channels.

Restraints are concentrated in upstream economics and purification economics. Glabridin is isolated from Glycyrrhiza glabra root, which is not a high-yield crop. Raw root prices vary with weather, irrigation access, and harvest labor costs. Market participants report that a 98% purity analytical grade can carry a tenfold price premium over a 20% grade. Capacity expansion for HPLC purification is capital-intensive and requires skilled analytical chemists. Small-scale producers find it difficult to meet registration requirements for Japan, Europe, and China simultaneously. In addition, a consumer trend toward total ingredient avoidance raises reputational risk for skin-lightening products, which can suppress demand even when the active molecule is safe. That concern is larger in Western markets than in Asia-Pacific.

• Alchem International Pvt. Ltd.: Integrates licorice extract production from root sourcing to high-purity isolation; supplies standardized glabridin for pharma and cosmetics.
• Sabinsa Corp.: Maintains a broad phytoceutical portfolio and uses its licorice extract experience to support clinical documentation for skin health actives.
• Kan Phytochemicals Pvt. Ltd.: An Indian botanical extraction specialist with HPLC purification capacity serving cosmetic and nutraceutical customers in Asia and Europe.
• Herbal Creations: Focuses on herbal actives and standardized powders, including glabridin grades for cosmeceutical formulators.
• Herbo Nutra: Provides customized particle size and blending options for glabridin in powder and capsule applications.
• Merck KGaA: Operates as a high-grade reference material supplier and offers analytical standards used for HPLC method calibration.
• Cayman Chemical Co: Supplies research-grade glabridin and related isoflavonoid controls for academic and clinical validation studies.
• Plamed Green Science Group: Uses green extraction technology to produce botanical extracts for personal care supply chains.
• Haihang Industry Co. Ltd.: A chemical trading and manufacturing company that supplies Chinese-produced glabridin across international distributors.
• Glentham Life Sciences Ltd.: Distributes fine chemicals and biochemicals, including glabridin, for laboratory and small-scale production use.
• M.C.Biotec Inc.: Positions as a biotechnology-oriented extract manufacturer with capabilities in fermentation-derived botanical actives.
• XI AN KINTAI BIOTECH INC.: Focuses on high-purity plant extracts and has invested in analyst-verified production lines for glabridin.
• Xi an Sost Biotech Co. Ltd.: Provides botanical extract toll manufacturing and specialty purification services for overseas cosmetic brands.

• March 2024: Export prices in the Licorice Root Extract Market rose because wild harvesting in Xinjiang contracted; cosmetic ingredient buyers diversified to cultivated roots in Kazakhstan and Inner Mongolia.
• July 2024: Kan Phytochemicals Pvt. Ltd. completed an expanded extraction bay targeting HPLC 98 percent glabridin for export to European cosmetics manufacturers.
• October 2024: A contract research organization in South Korea published stability data on glabridin-loaded nanoemulsions, supporting higher use in serum-type products.
• January 2025: XI AN KINTAI BIOTECH INC. added a third HPLC purification line, reducing lead times for 90 percent and 98 percent grades in Asia-Pacific.
• April 2025: Sabinsa Corp. introduced a fermented licorice extract blend with standardized glabridin, moving the ingredient further into clean-label claims.
• August 2025: EU-focused buyers began requiring animal-free safety data and heavy-metal residual certificates before adding new glabridin suppliers to approved lists.

Asia-Pacific is the largest revenue pool, contributing close to 35% of the 2024 global total, and is also the fastest-growing region. Japan and South Korea remain demanding buyers for high-purity cosmetic actives, while China supplies much of the licorice root extraction capacity. Local regulations on skin whitening claims remain stringent but the compliance burden favors manufacturers with qualified analytical laboratories. China's domestic beauty market is shifting from brightening claims to tone-evening and barrier-care positioning, a linguistic change that still permits glabridin use while reducing regulatory exposure.

Europe holds 27% of market value and represents the most mature consumption pattern for HPLC-purified glabridin. The EU Cosmetics Regulation requires a responsible person, safety assessment, and comprehensive stability data; those requirements make European buyers willing to pay a premium for lower heavy-metal content. North America follows with 24% of revenue and a more fragmented purchaser base of clinical-stage brands, compounding pharmacies, and research institutions. South America accounts for approximately 7%, with Brazil driving natural cosmetics demand, while Middle East and Africa also account for 7% and show the highest upside in specialty depigmentation clinics.

The fastest-growing corridor is China-ASEAN, supported by direct cross-border supply of purified root derivatives and regional duty structures. The mature North American and European corridors are growing near 3-4%, in line with overall cosmeceutical expansion. Asia-Pacific growth is projected in the 6-7% range, driven by new product registration and distribution through dermatology networks.

Cosmetic manufacturers form the largest end-user group, purchasing glabridin for serums, creams, and mask packs. Pharmaceutical customers are fewer but buy at higher purity and require complete regulatory dossiers. Contract manufacturing organizations are becoming an essential demand node because they formulate private-label products for multiple skincare brands, consolidating purchase volumes and standardizing qualification criteria.

Procurement decision-making has shifted toward formulation and regulatory teams rather than traditional purchasing departments. Buyers now evaluate three data points before price: assay purity via HPLC, certificates of analysis, and residual solvent profiles. The Cosmeceutical Ingredients Market is purchasing through specialized online sourcing platforms and digital catalogues, with an estimated 35-40% of orders now initiated through digital channels. In lower-purity segments, order frequency is high, but unit pricing remains sensitive to competitor offers from Chinese extract merchants. High-purity supply is less elastic because customers require supplier audits and full traceability before batch approval.

Three emerging technologies are reshaping glabridin production. Microbial fermentation based on engineered yeast or bacteria is the most disruptive, because it can replace variable licorice root feedstocks with a controlled bioprocess that avoids pesticide residue and heavy-metal contamination. Patent filings for this route grew sharply after 2023, mostly from synthetic biology developers in China and the United States. Commercial-scale adoption is still in the pilot stage, with a realistic timeline of 3-5 years before continuous fermentation batches meet cosmetic purity specifications.

Second, simulated moving bed chromatography offers a continuous purification alternative to batch HPLC. It can raise yiel%s by 20-30% per pass and lower solvent consumption. Third, enzyme-assisted extraction using cellulases and pectinases improves release of glabridin from root cell walls, reducing reliance on aggressive solvents. These technologies will expand the Biotech Botanical Extracts Market while reinforcing existing suppliers that invest early. Incumbents with proprietary HPLC databases and formulation expertise are not necessarily displaced, but they face margin pressure if biotech entrants deliver identical purity at a lower energy input. The next R&D cycle will therefore focus on process cost per kilogram and environmental footprint, not only assay purity.

• 1. Glabridin
  • 1.1. Cas 59870-68-7
• 2. Market Is Segmented By Type
  • 2.1. HPLC 20 percent
  • 2.2. HPLC 40 percent
  • 2.3. HPLC 60 percent
  • 2.4. HPLC 90 percent
  • 2.5. HPLC 98 percent
• 3. Application
  • 3.1. Cosmetics
  • 3.2. Pharmaceutical
• 4. Product Type
  • 4.1. Powder
  • 4.2. Liquid
  • 4.3. Capsule
  • 4.4. Others
  • 4.5. Middle East
  • 4.6. Africa

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific